Tranexamic acid (TXA) has become widely utilized in different specialities including facelift surgery. To robustly evaluate the quality of available evidence on the efficacy and safety of TXA use in facelift surgery. We searched MEDLINE, EMBASE, CINAHL, CENTRAL, Google Scholar, Science Citation Index and LILAC databases for randomized controlled trials (RCTs), and observational studies. Primary outcomes were blood loss, post-operative hematoma, ecchymosis, and swelling, in addition to technical considerations and complications. We assessed reviews quality using the AMSTAR 2 tool, studies quality using GRADE, and risk of bias using Cochrane’s Risk of Bias tool for RCTs and ROBINS-I for non-randomized studies. Of the 368 articles, a total of three studies including 150 patients met the inclusion criteria. The RCT reported a significant reduction in postoperative serosanguineous collections in the TXA group (p < 0.01), and the surgeon rated postoperative ecchymosis and bruising. The prospective cohort study reported reduced drainage output in first 24 hours in the TXA group (P < 0.01). The retrospective cohort study reported lower intraoperative blood loss, mean POD1 drain output, percentage of drain removal on POD1 and number of days to drain removal the TXA group (all, p < 0.01). The quality of studies was moderate, and this review was the highest rated compared to previous reviews, as per the AMSTAR2 tool. Based on limited literature, TXA improves clinical outcomes regardless of the route of administration. Topical TXA is an emerging route, expediting drain removal and reducing blood loss. Future Level I high-quality studies are required.